CytoLyt固定显著抑制MIB1免疫反应性而Ki-67克隆30-9不受影响:关键诊断意义
研究评估固定液和细胞块处理对Ki-67免疫反应性的影响,发现CytoLyt固定显著降低MIB1标记指数(均值10% vs 福尔马林47%),而Ki-67克隆30-9不受抑制。在CytoLyt固定的SCLC样本中,30-9显示预期反应范围(均值83%),MIB1明显受抑(均值60%)。建议使用CytoLyt的实验室选用Ki-67 30-9抗体而非MIB1。
要点
- CytoLyt固定显著抑制MIB1免疫反应性,平均标记指数降低37%。
- Ki-67克隆30-9在CytoLyt固定细胞块中不受抑制。
- 使用CytoLyt的实验室应选用Ki-67 30-9抗体而非MIB1。
核心结论
- CytoLyt固定显著抑制MIB1免疫反应性,而Ki-67克隆30-9不受抑制。
研究设计与样本
- 使用新鲜切除肿瘤制备测试细胞块(n=10),比较CytoLyt与福尔马林收集介质及MIB1与其他Ki-67克隆。
- 在CytoLyt固定的临床小细胞肺癌样本(n=14)中平行测试MIB1与Ki-67 30-9克隆。
- 共进行223次个体免疫细胞化学反应用于测试多种程序修改。
主要发现
- 223次免疫细胞化学反应用于测试的程序修改均未能恢复CytoLyt中的MIB1反应性,除非改用Ki-67 30-9抗体。
临床怎么用
- 使用CytoLyt的实验室推荐使用Ki-67 30-9抗体而非MIB1抗体。
- MIB1反应性显著差异可能导致SCLC诊断陷阱及其他肿瘤类型的错误预后分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Ki-67 proliferation marker has multiple diagnostic and prognostic applications. Although several clones to the Ki-67 antigen are commercially available, the MIB1 clone is widely recommended in the surgical pathology literature for neuroendocrine tumors. In our cytopathology practice, we have encountered unexpectedly low MIB1 immunoreactivity in CytoLyt-fixed cell blocks (CBs). The current study evaluated the impact of fixatives, CB processing, and immunocytochemical (ICC) procedures on Ki-67 immunoreactivity. METHODS: Test CBs were prepared from freshly resected tumors, and multiple variables in the MIB1 ICC procedure were tested, including CytoLyt versus formalin collection media, MIB1 versus other Ki-67 clones including 30-9, and other variables. MIB1 versus Ki-67 30-9 clones were tested in parallel on CytoLyt-fixed CBs from clinical samples of small cell lung carcinoma (SCLC). RESULTS: In the test CBs (n = 10), the mean MIB1 labeling index was 10% in CytoLyt versus 47% in formalin (P = .0116), with a mean loss of reactivity in matched CBs of 37% (up to 70%). None of the procedure modifications tested in 223 individual ICC reactions recovered MIB1 reactivity in CytoLyt except for switching to the Ki-67 30-9 antibody. In CytoLyt-fixed SCLC samples (n = 14), the Ki-67 30-9 antibody demonstrated expected ranges of reactivity (mean, 83%; range, 60%-100%), whereas MIB1 demonstrated markedly inhibited labeling (mean, 60%; range, 10%-95%) (P = .0058). CONCLUSIONS: CytoLyt fixation substantially inhibits MIB1 immunoreactivity, whereas the Ki-67 30-9 clone is not susceptible to inhibition. Markedly discrepant MIB1 reactivity may present a pitfall in the diagnosis of SCLC and may lead to the incorrect prognostic stratification of other tumor types. For laboratories using CytoLyt, we recommend using the Ki-67 30-9 antibody rather than the MIB1 antibody.
引用
- Buonocore DJ, Konno F, Jungbluth AA, et al. CytoLyt fixation significantly inhibits MIB1 immunoreactivity whereas alternative Ki-67 clone 30-9 is not susceptible to the inhibition: Critical diagnostic implications. Cancer Cytopathol. 2019. PMID: 31398281. doi:10.1002/cncy.22170
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。